Literature DB >> 25234560

National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary.

Terry A Jacobson1, Matthew K Ito2, Kevin C Maki3, Carl E Orringer4, Harold E Bays5, Peter H Jones6, James M McKenney7, Scott M Grundy8, Edward A Gill9, Robert A Wild10, Don P Wilson11, W Virgil Brown12.   

Abstract

Various organizations and agencies have issued recommendations for the management of dyslipidemia. Although many commonalities exist among them, material differences are present as well. The leadership of the National Lipid Association (NLA) convened an Expert Panel to develop a consensus set of recommendations for patient-centered management of dyslipidemia in clinical medicine. The current Executive Summary highlights the major conclusions in Part 1 of the recommendations report of the NLA Expert Panel and includes: (1) background and conceptual framework for formulation of the NLA Expert Panel recommendations; (2) screening and classification of lipoprotein lipid levels in adults; (3) targets for intervention in dyslipidemia management; (4) atherosclerotic cardiovascular disease risk assessment and treatment goals based on risk category; (5) atherogenic cholesterol-non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol-as the primary targets of therapy; and (6) lifestyle and drug therapies intended to reduce morbidity and mortality associated with dyslipidemia.
Copyright © 2014 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atherogenic cholesterol; Atherosclerotic cardiovascular disease; Clinical recommendations; Coronary heart disease; Dyslipidemia; Lipoproteins; Low-density lipoprotein cholesterol

Mesh:

Substances:

Year:  2014        PMID: 25234560     DOI: 10.1016/j.jacl.2014.07.007

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  147 in total

Review 1.  Cholesterol Management in the Era of PCSK9 Inhibitors.

Authors:  Anna Svatikova; Stephen L Kopecky
Journal:  Curr Cardiol Rep       Date:  2017-09       Impact factor: 2.931

2.  Dyslipidemia in the Arabian Gulf and its Impact on Cardiovascular Risk Outcome.

Authors:  Khalid Al-Rasadi; Hilal Al-Sabti
Journal:  Oman Med J       Date:  2015-11

Review 3.  Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data.

Authors:  Ashwin Durairaj; Alberto Sabates; Jonathan Nieves; Brian Moraes; Seth Baum
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-08

4.  A Comparative Overview of Prescription Omega-3 Fatty Acid Products.

Authors:  Matthew K Ito
Journal:  P T       Date:  2015-12

Review 5.  Assessing Cardiovascular Disease Risk and Responses to Preventive Therapies in Clinical Practice.

Authors:  Kevin C Maki; Mary R Dicklin
Journal:  Curr Atheroscler Rep       Date:  2018-03-20       Impact factor: 5.113

Review 6.  Is There an Ideal Low-Density Lipoprotein Cholesterol Level? Confusion regarding Lipid Guidelines, Low-Density Lipoprotein Cholesterol Targets, and Medical Management.

Authors:  Thomas F Whayne
Journal:  Int J Angiol       Date:  2016-12-12

Review 7.  Lipid Biomarkers for Risk Assessment in Acute Coronary Syndromes.

Authors:  Jeffrey W Meeusen; Leslie J Donato; Allan S Jaffe
Journal:  Curr Cardiol Rep       Date:  2017-06       Impact factor: 2.931

8.  Impact on Dyslipidemia After Laparoscopic Sleeve Gastrectomy.

Authors:  Agustina Vigilante; Franco Signorini; Marcos Marani; Virginia Paganini; Germán Viscido; Luciano Navarro; Lucio Obeide; Federico Moser
Journal:  Obes Surg       Date:  2018-10       Impact factor: 4.129

9.  Rationale, Design, and Implementation of Intensive Risk Factor Treatment in the CREST2 Trial.

Authors:  Tanya N Turan; Jenifer H Voeks; Marc I Chimowitz; Ana Roldan; Todd LeMatty; William Haley; Maria Lopes-Virella; Seemant Chaturvedi; Michael Jones; Donald Heck; George Howard; Brajesh K Lal; James F Meschia; Thomas G Brott
Journal:  Stroke       Date:  2020-09-21       Impact factor: 7.914

Review 10.  Statins to improve cardiovascular outcomes in treated HIV infection.

Authors:  Chris T Longenecker; Allison R Eckard; Grace A McComsey
Journal:  Curr Opin Infect Dis       Date:  2016-02       Impact factor: 4.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.